KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Finished Goods: 2015-2017

Historic Finished Goods for Travere Therapeutics (TVTX) over the last 3 years, with Dec 2017 value amounting to $1.9 million.

  • Travere Therapeutics' Finished Goods fell 11.17% to $1.4 million in Q1 2018 from the same period last year, while for Mar 2018 it was $1.4 million, marking a year-over-year decrease of 11.17%. This contributed to the annual value of $1.9 million for FY2017, which is 28.59% up from last year.
  • Travere Therapeutics' Finished Goods amounted to $1.9 million in FY2017, which was up 28.59% from $1.5 million recorded in FY2016.
  • Travere Therapeutics' Finished Goods' 5-year high stood at $2.2 million during FY2015, with a 5-year trough of $1.5 million in FY2016.
  • For the 3-year period, Travere Therapeutics' Finished Goods averaged around $1.9 million, with its median value being $1.9 million (2017).
  • As far as peak fluctuations go, Travere Therapeutics' Finished Goods slumped by 33.69% in 2016, and later increased by 28.59% in 2017.
  • Yearly analysis of 3 years shows Travere Therapeutics' Finished Goods stood at $2.2 million in 2015, then tumbled by 33.69% to $1.5 million in 2016, then increased by 28.59% to $1.9 million in 2017.